ATE244563T1 - Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne - Google Patents
Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräneInfo
- Publication number
- ATE244563T1 ATE244563T1 AT92906545T AT92906545T ATE244563T1 AT E244563 T1 ATE244563 T1 AT E244563T1 AT 92906545 T AT92906545 T AT 92906545T AT 92906545 T AT92906545 T AT 92906545T AT E244563 T1 ATE244563 T1 AT E244563T1
- Authority
- AT
- Austria
- Prior art keywords
- fluoxetine
- isomer
- pure
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79303691A | 1991-11-15 | 1991-11-15 | |
| PCT/US1992/000888 WO1993009769A1 (en) | 1991-11-15 | 1992-02-05 | Methods and compositions utilizing pure s(+) isomer fluoxetine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE244563T1 true ATE244563T1 (de) | 2003-07-15 |
Family
ID=25158891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92906545T ATE244563T1 (de) | 1991-11-15 | 1992-02-05 | Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1208838A3 (de) |
| JP (2) | JPH07500812A (de) |
| AT (1) | ATE244563T1 (de) |
| AU (2) | AU1373692A (de) |
| CA (1) | CA2123704C (de) |
| DE (1) | DE69233124T2 (de) |
| DK (1) | DK0612242T3 (de) |
| ES (1) | ES2197144T3 (de) |
| WO (1) | WO1993009769A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE392893T1 (de) * | 1993-06-28 | 2008-05-15 | Wyeth Corp | Neue behandlungsmethoden durch verwendung von phenethylaminderivaten |
| ES2082723B1 (es) * | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| ES2103682B1 (es) * | 1995-09-20 | 1998-04-01 | Lilly Sa | Composicion farmaceutica oral de fluoxetina, solida y con caracteristicas organolepticas mejoradas. |
| AR021155A1 (es) | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| US6846957B2 (en) | 2002-11-22 | 2005-01-25 | Board Of Regents, The University Of Texas System | Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor |
| CN111643475A (zh) * | 2020-07-20 | 2020-09-11 | 华益药业科技(安徽)有限公司 | 一种氟西汀胶囊生产工艺 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR75395B (de) * | 1980-11-14 | 1984-07-13 | Lilly Co Eli |
-
1992
- 1992-02-05 EP EP02003532A patent/EP1208838A3/de not_active Withdrawn
- 1992-02-05 DK DK92906545T patent/DK0612242T3/da active
- 1992-02-05 JP JP4506297A patent/JPH07500812A/ja active Pending
- 1992-02-05 AU AU13736/92A patent/AU1373692A/en not_active Abandoned
- 1992-02-05 DE DE69233124T patent/DE69233124T2/de not_active Expired - Fee Related
- 1992-02-05 EP EP92906545A patent/EP0612242B1/de not_active Expired - Lifetime
- 1992-02-05 WO PCT/US1992/000888 patent/WO1993009769A1/en active IP Right Grant
- 1992-02-05 ES ES92906545T patent/ES2197144T3/es not_active Expired - Lifetime
- 1992-02-05 CA CA002123704A patent/CA2123704C/en not_active Expired - Fee Related
- 1992-02-05 AT AT92906545T patent/ATE244563T1/de not_active IP Right Cessation
-
1997
- 1997-04-17 AU AU18917/97A patent/AU1891797A/en not_active Abandoned
-
2003
- 2003-08-28 JP JP2003304079A patent/JP2004002474A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69233124T2 (de) | 2004-02-19 |
| EP0612242A1 (de) | 1994-08-31 |
| CA2123704C (en) | 2003-01-21 |
| EP0612242B1 (de) | 2003-07-09 |
| DK0612242T3 (da) | 2003-10-20 |
| EP1208838A3 (de) | 2003-07-09 |
| EP0612242A4 (en) | 1997-01-15 |
| WO1993009769A1 (en) | 1993-05-27 |
| CA2123704A1 (en) | 1993-05-27 |
| DE69233124D1 (de) | 2003-08-14 |
| JPH07500812A (ja) | 1995-01-26 |
| EP1208838A2 (de) | 2002-05-29 |
| AU1891797A (en) | 1997-06-19 |
| ES2197144T3 (es) | 2004-01-01 |
| AU1373692A (en) | 1993-06-15 |
| JP2004002474A (ja) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE212223T1 (de) | Verwendung von sertraline zur herstellung eines arzneimittels zur behandlung von obsessiv- kompulsiven erkrankungen | |
| DE69012261D1 (de) | Verwendung von Sertralin zur Behandlung verfrühter Ejakulation. | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| DE59109222D1 (de) | Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen | |
| ATE399005T1 (de) | Pharmazeutische zusammensetzung aus einem beta-3- adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| ATE141505T1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
| ATE135908T1 (de) | Optisch reines r(-)albuterol zur behandlung von asthma | |
| EP0401903A3 (de) | Verwendung von Vanilloiden zur Behandlung von Erkrankungen der Atemwege | |
| ATE244563T1 (de) | Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne | |
| HUP0401934A2 (hu) | Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében | |
| DE69620027T2 (de) | Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs | |
| DE60100660D1 (de) | Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien | |
| ATE235237T1 (de) | Sertralin zur behandlung von post-myocard-infarkt-patienten | |
| BG98684A (en) | 3-(n-isopropyl-n-h-propylamino)-5-(n-isopropyl) carbonoylchroman | |
| DK0415612T3 (da) | Anvendelse af sertralin til behandling af afhængigheder af kemiske stoffer | |
| ATE192650T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
| DE69620394D1 (de) | Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht | |
| ATE232098T1 (de) | Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0612242 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |